Pharming Group NV Asset Resilience Ratio
Pharming Group NV asset resilience ratio. Pharming Group NV (PHAR) has an Asset Resilience Ratio of 24.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Pharming Group NV (PHAR) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pharming Group NV (2005–2025)
Asset resilience ratio of Pharming Group NV from 2005 to 2025. This chart shows how Pharming Group NV's Asset Resilience Ratio has changed over time. Read total liabilities of Pharming Group NV for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pharming Group NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Pharming Group NV balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $117.80 Million | 24.07% |
| Total Liquid Assets | $117.80 Million | 24.07% |
Asset Resilience Insights
- Good Liquidity Position: Pharming Group NV maintains a healthy 24.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Pharming Group NV Industry Peers by Asset Resilience Ratio
Compare Pharming Group NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Pharming Group NV Asset Resilience Ratio by Year (2005–2025)
Pharming Group NV asset resilience ratio by year from 2005 to 2025. The table below shows the annual Asset Resilience Ratio data for Pharming Group NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.76% | $33.79 Million | $499.81 Million | -21.48pp |
| 2024-12-31 | 28.24% | $112.95 Million | $399.99 Million | -4.53pp |
| 2023-12-31 | 32.77% | $151.68 Million | $462.85 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $425.80 Million | -- |
| 2019-12-31 | -0.26% | $-661.91K | $255.91 Million | -5.84pp |
| 2008-12-31 | 5.59% | $5.22 Million | $93.40 Million | -11.30pp |
| 2005-12-31 | 16.88% | $6.92 Million | $40.96 Million | -- |
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more